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Although loss of CDH1 promotes cancer metastasis by disrupting cell–cell adhesion and inducing
transcriptional changes, the functional pathways involved in the loss of CDH1 affecting EGFR expres-
sion in lung cancer cells still remain largely unknown. In this study, we report that down-regulation
of CDH1 promoted EGFR transcription through activation of YBX1. Furthermore, knockdown of
CDH1 activated the AKT signaling pathway, and inhibition of AKT suppressed the phosphorylation
of YBX1 and the up-regulation of EGFR induced by CDH1 loss. These data demonstrate that loss of
CDH1 induces EGFR expression via phospho-YBX1, which is activated through the AKT signaling
pathway.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction It has been shown that there is cross-talk between the CDH1CDH1/E-cadherin is a cell–cell adhesion trans-membrane
protein that also plays role in cellular signal transduction in
EGFR/ERK and c-Src-mediated pathways. Loss of CDH1 promotes
translocation of b-catenin into the nucleus, regulating transcrip-
tion of various targeted proteins [1]. Importantly, loss of CDH1 is
also involved in epithelial–mesenchymal transition (EMT) which
is the critical early step for cancer metastasis [2]. Hence, low
expression level of CDH1 is prominently associated with tumor
invasiveness, metastatic dissemination, and poor patient progno-
sis. However, the mechanism that loss of CDH1 promotes NSCLC
metastasis needs further investigation.
Epidermal growth factor receptor (EGFR/ErbB-1/HER1) belongs
to ErbB family which consists of four transmembrane proteins with
intracellular tyrosine kinase activity [3]. Once activated, EGFR
intracellular tyrosine kinase domain is autophosphorylated and re-
sults in activation of several downstream signaling pathways,
including the PI3K, STAT and the mitogen-activated protein kinase
pathways, which regulate biological responses such as prolifera-
tion, cell migration, cell survival and differentiation [1]. EGFR
mutation or over-expression is associated with many human
malignancies including NSCLC [4].and EGFR pathways during carcinogenesis, e.g., activation of EGFR
reduced CDH1 levels through TWIST [5]. In addition, CDH1 and
EGFR have physical interaction through extracellular domains,
and the tyrosine-kinase activity of EGFR promotes the endocytosis
of CDH1 [6]. Moreover, 48% of all squamous cell carcinoma of the
head and neck (SCCHN) samples have over-expression of EGFR
and decreased-expression of CDH1 [7], and down-regulation of
CDH1 leads to the up-regulation of EGFR and eventually enhances
proliferation of SCCHN cells [8]. However, CDH1’s role in regulating
EGFR in NSCLC cells remains unclear.
Y-box binding protein-1 (YBX1) is over-expressed in various
tumors including lung cancers and serves as a novel marker of lung
cancer progression [9]. Previous study has shown that YBX1 trans-
activated EGFR expression in breast cancer [10]. Additionally, AKT
phosphorylates YBX1 at serine 102 and triggers import of YBX1 into
the nucleus in breast cancer and ovarian cells [11,12]. In this study,
we show that down-regulation of CDH1 up-regulated EGFR tran-
scription levels inNSCLC cells.We also demonstrate that YBX1plays
a critical role in EGFR up-regulation, which consequently promotes
cell proliferation and invasion ability in NSCLC cells.2. Methods and materials
2.1. Antibodies
Rabbit polyclonal anti-EGFR antibody was purchased from San-
ta Cruz Biotechnology. Rabbit polyclonal antibodies against YBX1,
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from Cell Signaling Technology. Mouse monoclonal anti-CDH1
antibody was purchased from BD Transduction Laboratories.
Rabbit anti-YBX1 antibody used in chromatin immunoprecipita-
tion assay was purchased from Sigma. Rabbit polyclonal anti-
AKT1 (phospho S473) antibody was purchased from Abcam.
2.2. Cell lines and cell culture
The human NSCLC cell lines were purchased from the American
Type Culture Collection (Manassas, VA) and A549 cell line was
recently authenticated in Microread Gene Technology (Beijing,
China) by STR analysis.
2.3. Establishment of cell lines with stable inhibition of CDH1
The plasmids of pMD2.G, pCMV-dR8.9, pLKO.1 puro and pLKO.1
puro-based CDH1 shRNA were obtained from Addgene. The target
sequence of shRNA directs against CDH1: 50-AAGATAGGAGTTCTCT-
GATGC-30. The lentivirus were produced in 293FT cells according to
the manufacturer’s instructions. The cells with loss of CDH1 were
selected and pooled after treatment with puromycin. The A549/
shCDH1 cells with stable inhibition of CDH1 and A549/pLKO.1 cells
without expression of shCDH1 RNA were used in subsequent
research.
2.4. Construction of lentiviral CDH1 expression vectors
The CDH1 coding region was ampliﬁed by PCR from A549 cDNA
using the primers: sense, 50-CACTAGTGCCGCCACCATGGGCCCTTG
GAGCCGCAG-30 and antisense, 50-GCTCGAGCTAGTCGTCCTCGCCG
CCTC-30. The ampliﬁed fragment was cloned into pLenti/V5 vector
(Invitrogen) and the construct of pLenti-CDH1 was produced. In
this experiment, we utilized pLenti-LacZ as a vector control.
2.5. Western blot analysis
Preparation of whole-cell protein lysates and the procedures for
the Western blotting were previously described [13].
2.6. Gene silencing by siRNA
All the siRNAs were synthesised by GenePharma (Shanghai, Chi-
na). CDH1 #1 and #2 siRNA duplexes target the sequence 50-CAGA-
CAAAGACCAGGACTA-30 and 50-GCACGUACACAGCCCUAAU-30,
respectively. EGFR #1 and #2 siRNA duplexes target the sequence
50-CCTTAGCAGTCTTATCTAA-30 and 50-GCUACGAAUAUUAAACA-
CUUC-30, respectively. YBX1 #1 and #2 siRNA duplexes target the
sequence 50-AGAAGGTCATCGCAACGAA-30 and 50-GGUCAUCG-
CAACGAAGGUU-30, respectively. AKT1 #1 and #2 siRNA duplexes
silencing the sequence 50-AATGCCCTTCTACAACCAGGA-30 and 50-
AAGCACCGCGTGACCATGAAC-30, respectively. The transfection of
siRNA was conducted as previously described [13].
2.7. Detection of EGFR mRNA expression
Cells were transfected with scramble siRNA and CDH1 siRNA for
48 h and the total RNA was isolated. The cDNA was ampliﬁed by
PCR using the speciﬁc primers: EGFR sense 50-TGTTTGGGACC
TCCGGTCAG-30, EGFR antisense 50-GGCAGGTCTTGACGCAGTGG-30,
b-actin sense 50-GAAACTACCTTCAACTCCATC-30, and b-actin anti-
sense 50-CTAGAAGCATTTGCGGTGGACGATGGAGGGGCC-30.
2.8. Luciferase assay
The wild-type and mutant forms of the ﬁrst 1 kb EGFR promoter
were constructed into pGL-3 basic reporter plasmid. Brieﬂy, A549and H358 cells were transiently co-transfected with test plasmid
and pCH110 plasmid expressing the LacZ which was utilized to
normalize transfection efﬁciency. Then, cells were reseeded and
transfected with scramble and CDH1 siRNA in following two days.
After 24 h, the transfected cells were harvested and the luciferase
activity was measured by Promega luciferase assay system.
2.9. Chromatin immunoprecipitation (ChIP)
A549 cells transfected with CDH1 siRNAwere subjected to chro-
matin immunoprecipitation assay (Millipore) following the manu-
facturer’s instruction. The following speciﬁc primers were
designed to amplify the EGFR promoter sequencewhichwas immu-
noprecipitated with speciﬁc YBX1 antibody: EGFR 1b sense 50-
TCGCCGCCAACGCCACAAC-30, EGFR 1b antisense 50-ACACGCC
CTTACCTTTCTTTTCCTCCAG-30, EGFR 2a sense 50-CCGCGAGTTTCC
CTCGCATTTCT-30, EGFR 2a antisense 50-CCTTCCCCCTTTCCCTTC
TTTTGTTTTAC-30. b-actinwas used as an housekeeping gene, b-actin
sense 50-GAAACTACCTTCAACTCCATC-30, and b-actin antisense
50-CTAGAAGCATTTGCGGTGGACGATGGAGGGGCC-30.
2.10. SRB assay
Cells transfected with CDH1 siRNA for 24 h were reseeded in
96-well plates. The cell growth rate was assessed utilizing Sulfo-
rhodamine B (SRB) assay.
2.11. Cell proliferation assay
Cells after transfection with siRNA for 24 h were reseeded in 96-
well plates and cultured for 14 h. Then the cell proliferation was
detected by BrdU cell proliferation assay kit (Roche) following
the manufacturer’s manual.
2.12. Cell scratch assay
Cells grew to conﬂuence in 6-well plates and a wound was
made by removing cells with 200-ll sterile tips subsequently. A
series of pictures at the same site of wound were taken every
12 h for 72 h. Cells that have migrated over the edge of the scratch
were counted at all time points.
2.13. Cell invasion assay
The cell metastatic potential was estimated by invasion assay
which was conducted with Matrigel-coated 24-well inserts con-
sisting of 8-lm pores according to the manufacturer’s protocol
(BD Biosciences).
3. Results
3.1. Loss of CDH1 induces EGFR transcriptional up-regulation in NSCLC
cells
We previously reported that down-regulation of CDH1 enforces
transcription of EGFR and cell proliferation in head and neck cancer
cells [8]. Therefore, to determine whether down-regulation of
CDH1 enhances EGFR expression in NSCLC cells as well, we inhib-
ited CDH1 expression in A549, H358, H322M, HCC827 and H1650
cells using RNAi technique and examined EGFR expression using
western blot assay. All the cell lines with reduced CDH1 expression
showed higher levels of EGFR than the control cells (Fig. 1A). In
addition, we constructed A549/shCDH1 and H1650/shCDH1 cells
using lenti-shRNA expression system which are stably absent of
CDH1 due to persistently expressed CDH1 shRNA. A549/pLKO.1
and H1650/pLKO.1 cells which maintain normal CDH1 expression
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exhibited distinct up-regulation of EGFR expression (Fig. 1B). Con-
sistently, when CDH1 was over-expressed in H157, H1792 and
Calu-1 cells in which CDH1 was not expressed, EGFR was down-
regulated obviously (Fig. 1C). Further detections were conducted
to examine whether CDH1 knockdown played an important role
in EGFR transcriptional process. Reverse transcription-PCR
(RT-PCR) was performed to measure EGFR mRNA levels in A549,
H358 and H322M cells, and we found that reduction of CDH1
elicited a signiﬁcant increase in EGFRmRNA (Fig. 1D), indicating that
loss of CDH1 enhances the expression of EGFR at transcription level.
In addition, EGFR induces activation of its downstream targets such
as Ras/Raf/MEK/MAPK and the intracellular kinase Src, which con-
tribute to cell proliferation, survival, migration and invasion
[14,15]. Given depletion of CDH1 promoted EGFR expression, we
examined the phosphrylation of ERK and Src. We found up-regula-
tion of EGFR caused by loss of CDH1 activated ERK and Src
(Fig. 1E), suggesting that loss of CDH1 up-regulates EGFR expression
level, leading to reactivation of EGFR signaling pathway as well.
3.2. Loss of CDH1 up-regulates EGFR transcription via YBX1
phosphorylation
Given that CDH1 loss contributed to EGFR transcriptional
advantage, we further questioned whether down-regulation of
CDH1 inﬂuenced the transcription of EGFR. Previous reports
demonstrated that YBX1 acts as the pivotal transcriptional factor
of EGFR [10]. Our data show A549/shCDH1 and H1650/shCDH1
cells enhanced the phosphorylation of YBX1 compared with
A549 pLKO.1 and H1650 pLKO.1 cells (Fig. 2A). In addition, exog-
enous expression of CDH1 attenuated the phosphorylation of
YBX1 in H157, H1792 and Calu-1 cells (Fig. 2B). In comparison
with H157/Lac Z and Calu-1/Lac Z cells, H157/CDH1 and Calu-1/A
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expression with siRNA and found that blocking YBX1 impaired
the induction of EGFR that was caused by the loss of CDH1
(Fig. 3A and B). These results clearly showed that suppression
of CDH1 induced EGFR transcriptional expression in a phospho-
YBX1-dependent manner. It was demonstrated that YBX1 medi-
ated EGFR expression through directly binding to the ﬁrst 1 kb
of EGFR promoter, so we inspected the function of the two consid-
erable YBX1 responsive elements (YREs) (Fig. 2D) in the process
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chromatin immunoprecipitation assay was performed with YBX1
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pathway
Previous studies show EGFR transcriptional expression is regu-
lated through AKT pathway that phosphorylates YBX1 at serine
102 [11]. However, it is unclear whether this signaling occurs
when CDH1 is down-regulated. We thereby detected the level of
phospho-AKT (S473) in A549/shCDH1 and H1650/shCDH1 cells.As expected, CDH1 loss enhanced the phosphorylation of AKT
(Fig. 2A). Consistently, when CDH1 was over-expressed in H157,
H1792 and Calu-1 cells, the phosporylation of AKT was distinctly
impaired (Fig. 2B). Moreover, H157/CDH1 and Calu-1/CDH1 cells
with stable CDH1 expression showed weaker phospho-AKT level
compared with control cells (Fig. 2C). To determine whether phos-
pho-AKT played a critical role in activating YBX1 when CDH1 was
blocked in NSCLC cells, we suppressed AKT expression with siRNA
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and EGFR was both attenuated in AKT-siRNA transfected cells
(Fig. 3A and B). We thereby conclude that loss of CDH1 activates
AKT signaling and further phosphorylates YBX1.
3.4. YBX1 and EGFR contribute to proliferation, migration and
invasiveness promoted by CDH1 reduction in NSCLC cells
Our evidence revealed that reduction of CDH1 may contribute
to tumor progression and metastasis through regulating YBX1
and EGFR. To test the speciﬁc role of YBX1 and EGFR in cancer cells,
we transfected YBX1 and EGFR siRNA in A549 cells respectively. As
expected, the proliferation of A549 cells treated with CDH1 siRNA
was enhanced compared with the control cells, while additional
YBX1 or EGFR knockdown abrogated the proliferation enhance-
ment induced by CDH1 reduction (Fig. 4A). Meanwhile, cell inva-
sive capacity was measured by matrigel-coated chambers. The
results showed that invasive capacity of CDH1-silenced A549 cells
was improved compared with the control cells. However, addi-
tional YBX1 or EGFR siRNA transfected cells had obviously reduced
cell invasive competence than cells interfered with CDH1 alone
(Fig. 4B). Furthermore, cell scratch assay was utilized to examine
cell motility. As shown in Fig. 4C, compared with A549/shCDH1
cells, further inhibition of either YBX1 or EGFR greatly decreased
the cell migration potential respectively. Therefore, we conclude
that CDH1 loss promotes NSCLC cell proliferation and invasiveness,
which is concomitant with activation of YBX1 and increased
expression of EGFR.
4. Discussion
CDH1 functions as a tumor suppressor protein [16]. Loss of
CDH1 triggers epithelial–mesenchymal transitions (EMT) and isstrongly association with invasive metastasis and poor prognosis
in many tumors [17,18]. Moreover, decreased expression of
CDH1 is responsible for the malignant phenotype of non-small-cell
lung cancer [19]. In this study, we show that down-regulated CDH1
strengthens EGFR transcription in a phospho-YBX1 dependent way
and contributes to cell proliferation and metastasis in NSCLC cells.
EGFR is correlated with accelerating cell growth, motility and inva-
sion [20]. In our present research, we manifested that interfering
CDH1 expression facilitated EGFR expression and activated ERK
and Src, and then enhanced cell growth, propagation and migra-
tion. Hence, we propose that the increase of EGFR may participate
in the activation of downstream effectors which is pivotal to cancer
cell survival and metastasis.
We used two CDH1 siRNAs to transfect the cells to examine the
short-term effects that CDH1 knockdown brought. And we used
pLKO.1-shCDH1 lentivirus to infect the cells and got a pool of cells
after selection with puromycin that could stably knock down the
CDH1 expression. We used this pooled cell line to see the long-
term effects that CDH1 knockdown brought. Our data show that
either short-term or long-term knockdown of CDH1 could up-reg-
ulate EGFR expression in targeting cells.
Y-box binding protein-1 (YBX1) is an oncogenic protein that is
over-expressed in various tumors including lung cancers and serves
as a novel marker of lung cancer progression [9]. In this study, we
found that inhibition of CDH1 increased the interaction between
transcription factor YBX1 and the EGFR promoter, causing trans-acti-
vation of EGFR expression. Our data demonstrate that inhibition of
YBX1 decreased proliferation of CDH1-silenced NSCLC cells. In addi-
tion, inhibition of YBX1 attenuated cell migration and invasion abil-
ity of cancer cells. Therefore, we propose that YBX1 plays a central
role in NSCLC development and may serve as a therapeutic target.
Taken together, we show that the loss of CDH1 increased
expression of EGFR via AKT signaling pathway and subsequent
4000 X. Liu et al. / FEBS Letters 587 (2013) 3995–4000activation of YBX1. This pathway cascade promotes proliferation
and metastasis in NSCLC cells. We conclude that blocking EGFR
and YBX1 expression can effectively interrupt tumor potential of
NSCLC cells by slowing growth, migration and invasion. These
ﬁndings provide foundations for novel approaches in treatment
strategies for cancers such as NSCLC.Role of the funding source
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